Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Undersøgelse efter godkendelse af TREO Abdominal Stent-Graft System (TREO PAS)

10. november 2026 opdateret af: Bolton Medical

Post-godkendelsesundersøgelse af TREO abdominal stent-graft-system (P190015) hos patienter med infrarenale abdominale aorta- og aorto-iliaca-aneurismer

The purpose of this study is to determine the long-term performance of the TREO Abdominal Stent-Graft as a treatment for patients with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Detaljeret beskrivelse

This is a prospective, multi-center, non-randomized, single-arm, post-market, non-interventional study of treatment with the TREO Abdominal Stent-Graft in subjects with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms. The study will include a minimum of 300 subjects treated with the TREO Abdominal Stent-Graft at up to 55 investigational sites in the US.

The primary objective is the collection of real world safety and effectiveness outcomes of the TREO Abdominal Stent-Graft System in an all-comers population eligible for the endovascular treatment of AAA in routine clinical practice, with emphasis on subjects that experience a device stent-strut or barb fracture.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

338

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85006
        • Vascular Surgery Specialists
      • Tucson, Arizona, Forenede Stater, 85718
        • Pima Heart and Vascular
    • California
      • Fresno, California, Forenede Stater, 93701
        • University of California, San Francisco-Fresno
      • La Jolla, California, Forenede Stater, 92037
        • University of California, San Diego
      • San Diego, California, Forenede Stater, 92161
        • VA San Diego
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • University of Colorado Anschutz
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06520
        • Yale University
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20010
        • Medstar Washington Hospital Center
    • Florida
      • Gainesville, Florida, Forenede Stater, 32610
        • University of Florida
      • Gainesville, Florida, Forenede Stater, 32608
        • Malcom Randall VA Medical Center
      • Pensacola, Florida, Forenede Stater, 32504
        • Coastal Vascular and Interventional
      • Tampa, Florida, Forenede Stater, 33606
        • University of South Florida / Tampa General Hospital
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30342
        • Northside Hospital
      • Atlanta, Georgia, Forenede Stater, 30309
        • Piedmont Heart Institute
    • Iowa
      • Iowa City, Iowa, Forenede Stater, 52242
        • University of Iowa Hospital and Clinic
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, Forenede Stater, 02111
        • Tufts Medical Center
    • Michigan
      • Bay City, Michigan, Forenede Stater, 48708
        • McLaren Bay Region
      • Detroit, Michigan, Forenede Stater, 48202
        • Henry Ford Hospital
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater, 55407
        • Minneapolis Heart Institute Foundation
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63110
        • Barnes Jewish Hospital at Washington University
    • New Jersey
      • Hackensack, New Jersey, Forenede Stater, 07601
        • Hackensack University Medical Center
      • New Brunswick, New Jersey, Forenede Stater, 08901
        • Rutgers Robert Wood Johnson Medical Center
    • New York
      • New York, New York, Forenede Stater, 10075
        • Lenox Hill Hospital / Northwell Health
      • Stony Brook, New York, Forenede Stater, 11794-8191
        • Stony Brook Medical Center
      • Syracuse, New York, Forenede Stater, 13210
        • SUNY Upstate Medical University
      • The Bronx, New York, Forenede Stater, 10467
        • Montefiore Medical Center
    • North Carolina
      • Asheville, North Carolina, Forenede Stater, 27607
        • Mission Health
      • Greenville, North Carolina, Forenede Stater, 27834
        • East Carolina University
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73104
        • University of Oklahoma Health Sciences Center
    • Oregon
      • Portland, Oregon, Forenede Stater, 97239
        • Oregon Health and Science University
      • Portland, Oregon, Forenede Stater, 97239
        • VA Portland Healthcare System
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19140
        • Temple University Hospital
      • Pittsburgh, Pennsylvania, Forenede Stater, 15232
        • University of Pittsburgh Medical Center
    • Tennessee
      • Kingsport, Tennessee, Forenede Stater, 37660
        • Wellmont Cardiology Services
    • Texas
      • Austin, Texas, Forenede Stater, 78756
        • St. David's Healthcare (Cardiothoracic and Vascular Surgeons)
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84132
        • University of Utah Hospital
    • Virginia
      • Norfolk, Virginia, Forenede Stater, 22042
        • Sentara Heart Hospital
      • Richmond, Virginia, Forenede Stater, 23282
        • Virginia Commonwealth University
    • Wisconsin
      • Milwaukee, Wisconsin, Forenede Stater, 53226
        • Medical College of Wisconsin

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Willing and able to comply with all study procedures and visits.
  • Written informed consent to participate in the study.
  • Patient's aneurysm can be treated with the TREO Abdominal Stent-Graft System.
  • Adequate data (medical records/imaging studies) available to analyze the primary endpoints for patients enrolled retrospectively.

Exclusion Criteria:

• Medical, social or psychological problems that, in the opinion of the investigator, preclude patient from receiving treatment with the TREO Abdominal Stent-Graft System.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Subjects who receive the TREO Abdominal Stent-Graft System

Eligible subjects will be implanted with the TREO Abdominal Stent-Graft System.

The TREO Abdominal Stent-Graft System is intended for the treatment of infrarenal abdominal aortic aneurysms with or without iliac involvement.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of stent-strut fracture or barb separation as confirmed by the Imaging Core Laboratory.
Tidsramme: Through 5 Years post-procedure

Incidence of fracture in a stent-strut or separation of one or more proximal fixation barbs as confirmed by the Imaging Core Laboratory upon review of post-implant imaging studies.

Through 5 Years post-procedure
Incidence of secondary intervention for adverse events related to or caused as a result of stent-strut fracture or barb separation.
Tidsramme: Through 5 Years post-procedure

Incidence of secondary intervention for adverse events related to or caused as a result of a fracture in a stent-strut or separation of one or more proximal fixation barbs. Relatedness to the device will be confirmed by the Clinical Events Committee (CEC) through review of available treatment and procedure records and reports of imaging studies.

Through 5 Years post-procedure

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of participants with technical success at the conclusion of the index procedure
Tidsramme: Through 5 Years post-procedure

Defined as the following:

  • successful delivery (i.e., ability to deliver the implant to the intended location without the need for unanticipated corrective intervention related to delivery);
  • successful and accurate deployment (deployment of the endovascular stent graft in the planned location; patency of the endovascular stent graft, absence of device deformations such as kinks, stent eversion, mal-deployment, misaligned deployment, requiring unplanned placement of an additional device within the endovascular stent graft, and
  • successful withdrawal (i.e. successful withdrawal of the delivery system, without the need for unanticipated corrective intervention related to withdrawal)
Through 5 Years post-procedure
Major Adverse Events
Tidsramme: Through 5 Years post-procedure

Incidence of the following Major Adverse Events

  • Myocardial infarction according to SCAI definition
  • Stroke according to the VARC-2 guidelines
  • New Onset Renal Failure requiring permanent dialysis
  • New onset Respiratory Failure requiring permanent home oxygen therapy through 30 days
  • Permanent Paralysis/Paraplegia
  • Bowel Ischemia
  • Procedural blood loss (≥ 1000cc)
Through 5 Years post-procedure
Incidence of procedure-related clinical utility measures
Tidsramme: Through 5 Years post-procedure

Reporting of procedural data collected during implant of the TREO Abdominal Stent-Graft System including: Procedure time (minutes), Fluoroscopy time (minutes), Contrast volume (mL), Access method (i.e. percutaneous, surgical cut down), Length of ICU stay (hours), Length of hospital stay post-procedure (days), Anesthesia Type.

Through 5 Years post-procedure
Incidence of procedure-related complications
Tidsramme: Through 5 Years post-procedure

Incidence of adverse events occurring during or following the implant determined by the CEC to be procedure-related.

Through 5 Years post-procedure
Incidence of successful aneurysm treatment
Tidsramme: 12 months post-implant

Successful aneurysm treatment is defined as:

  • Technical success
  • Absence of death from the initial procedure, secondary intervention or aortic-related cause.
  • Absence of persistent type I or III endoleaks
  • Absence of aneurysm sac expansion >5 mm
  • Absence of device migration >10mm
  • Absence of failure due to device integrity issues
  • Absence of aneurysm rupture
  • Absence of conversion to open surgical repair
  • Absence of permanent paraplegia, disabling stroke or dialysis that resulted from the initial operation or a secondary intervention to treat the original aortic pathology.
12 months post-implant
Incidence of all-cause mortality
Tidsramme: Through 5 Years post-procedure

Rate of mortality attributed to any causality as confirmed by the CEC.

Through 5 Years post-procedure
Incidence of aneurysm-related mortality
Tidsramme: Through 5 Years post-procedure

Rate of mortality attributed to the following causes as confirmed by the CEC: death due to a rupture, death within 30 days or prior to hospital discharge from primary procedure, or death within 30 days or prior to hospital discharge for a secondary procedure designed to treat the original aneurysm.

Through 5 Years post-procedure
Incidence of aneurysm rupture
Tidsramme: Through 5 Years post-procedure

Incidence of rupture of the native aneurysm sac post-implantation of the endograft as confirmed by the CEC.

Through 5 Years post-procedure
Incidence of secondary interventions.
Tidsramme: Through 5 Years post-procedure

Incidence of secondary procedures designed to treat or repair the original aneurysm treated with the TREO Abdominal Stent-Graft System

Through 5 Years post-procedure
Incidence of conversion to open surgical repair.
Tidsramme: Through 5 Years post-procedure

Incidence of conversion to open surgical AAA repair during the initial EVAR procedure secondary to any procedure-related complications as determined by the CEC.

Through 5 Years post-procedure
Incidence of stent-graft occlusion (i.e., loss of patency)
Tidsramme: Through 5 Years post-procedure

Incidence of stent-graft occlusion defined as the unintentional obstruction of the vascular/endograft lumen with minor obstruction (0-25%), minimal obstruction (26-74%), moderate obstruction (75-99%) or occlusion (100%) as confirmed by the Imaging Core Lab due to causes such as twisting or kinking of the prosthesis, oversizing and fabric pleating, or failure of the implant to fully open, or to mural thrombus deposition.

Through 5 Years post-procedure
Incidence of device stenosis or kink
Tidsramme: Through 5 Years post-procedure

Incidence of stenosis or kinking of the TREO Stent-Graft as confirmed by the Imaging Core Lab.

Through 5 Years post-procedure
Incidence of loss of device integrity
Tidsramme: Through 5 Years post-procedure

Incidence of changes in the structural integrity in a material component of the stent-graft such as a stent-strut fracture or separation of the proximal fixation barbs as confirmed by the Imaging Core Lab.

Through 5 Years post-procedure
Incidence of aneurysm enlargement (>5mm as compared to 30-day imaging).
Tidsramme: Through 5 Years post-procedure

Incidence of the increase in the aneurysm sac diameter > 5 mm at post-implant follow-up visits relative to the diameter determined at the first post-procedural imaging study, as confirmed by the Imaging Core Lab.

Through 5 Years post-procedure
Incidence of stent-graft migration (>10mm as compared to 30-day imaging)
Tidsramme: Through 5 Years post-procedure

Incidence of the longitudinal movement of all or part of a stent or attachment system for a distance of >10 mm relative to anatomical landmarks that were determined at the first post-procedural imaging study as confirmed by the Imaging Core Lab.

Through 5 Years post-procedure
Incidence of Type I, II, III, IV or V Endoleaks
Tidsramme: Through 5 Years post-procedure

Incidence of Type I, II, III, IV or V Endoleaks defined as the persistence of blood flow outside the lumen of the stent-graft but within the native aorta or adjacent vascular segment being treated by the stent-graft as determined by the Imaging Core Lab.

Through 5 Years post-procedure

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Gretchen Wild, Terumo Aortic

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

20. januar 2021

Primær færdiggørelse (Anslået)

31. oktober 2028

Studieafslutning (Anslået)

31. oktober 2028

Datoer for studieregistrering

Først indsendt

10. december 2020

Først indsendt, der opfyldte QC-kriterier

5. januar 2021

Først opslået (Faktiske)

6. januar 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

13. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • IP-0021-20

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner